Dr. Anisha Seth, A17106, Dr. Ajay Aurora, Dr. Neeraj Sanduja
Choroid plays a vital role in the pathophysiology of many retinal conditions.Its role in CNV is under evaluation.In this prospective case series,15 eyes with pathological myopia and subfoveal CNV were included, and given a single injection of Intravitreal Ranibizumab 0.3 mg/0.05ml.All eyes were followed up at 1 month with respect to best corrected visual acuity (BCVA), central macular thickness(CMT) and subfoveal choroidal thickness(CT) measured on SD-OCT.
The mean age of patients was 46.3± 16.5 years.The mean spherical equivalent was -16.22 DS (Range 10-20 DS).The mean baseline BCVA improved from 0.166± 0.12 to 0.378± 0.15 (p=0.000).The mean CMT pre-injection was 347.44 ± 92.88 µ that decreased to 292.18 ± 37.2 µ(p=0.016).The mean CT pre-injection was 145.18 ± 31.2 µ that decreased to 123.89 ± 33.5 µ at 1 month (p=0.000).
To conclude, Intravitreal Ranibizumab decreases the choroidal thickness along with retinal thickness, in patients with responsive myopic choroidal neovascularisation.